Clinical trials: Water
Burns
Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn
The purpose of the study is to see if a medication (Recombinant Coagulation Factor VIIa or NovoSeven), normally used to stop bleeding in persons with a bleeding disorder, will lower the amount of blood lost during burn surgery.
- Trial name
- NCT00243243
- Testing
- Recombinant Factor VIIa
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- United States Army Institute of Surgical Research
Healthy
A Study of Selpercatinib (LY3527723) in Healthy Participants
The main purpose of this study is to determine how safe and how well tolerated selpercatinib is when given as oral doses to healthy participants.
- Trial name
- NCT05338515
- Testing
- Selpercatinib
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
HIV Infections
A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)
This study will evaluate: (1) the effect of co-administration of single doses of calcium carbonate antacid and magnesium/aluminum hydroxide antacid on the steady-state plasma pharmacokinetic profile of raltegravir in human…
- Trial name
- NCT01622673
- Testing
- Raltegravir, TUMS® Ultra Strength, MINTOX® Maximum Strength
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain
Development of an S. sonnei human challenge model using a newly manufactured lyophilized lot of S. sonnei strain 53G (Lot 1794) that can be used in the future as a challenge strain for all S. sonnei vaccine candidates.
- Trial name
- NCT02816346
- Testing
- Shigella sonnei 53G
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- PATH
Nasolabial Folds
Extension Study for 43USSA1705
To evaluate the long-term safety of Sculptra Aesthetic as a single regimen for correction of Nasolabial Fold (NLF) contour deficiencies after changes in reconstitution and injection procedures compared to the approved label.
- Trial name
- NCT04225273
- Testing
- Sculptra Aesthetic, Lidocaine HCL
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Galderma R&D
Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy
Lidocaine for Oxaliplatin-induced Neuropathy
Oxaliplatin-induced neuropathy is a major dose-limiting side effect in patients with colorectal cancer treated with the FOLFOX chemotherapy regimen.
- Conditions
- Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer
- Trial name
- NCT03254394
- Testing
- Lidocaine Hydrochloride, FOLFOX regimen
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Radiotherapy Induced Mucositis, Head and Neck Cancer
A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer
The primary hypothesis of this study is that regular topical oral application of Manuka Honey will reduce the severity and duration of oral mucositis in patients who are undergoing mucotoxic radiation therapy for cancer treatment.
- Trial name
- NCT00615420
- Testing
- manuka honey
- Where
- 2 sites in Canada
- Volunteers
- 106 people
- Sponsor
- British Columbia Cancer Agency
Infection, Human Immunodeficiency Virus, HIV Infections
Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults
GSK2838232 is a novel HIV-1 maturation inhibitor (MI) that is being developed for the treatment of HIV-1 infection in combination with other antiretroviral therapy (ART).
- Trial name
- NCT03045861
- Testing
- GSK2838232, Cobicistat
- Where
- 14 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Sleep Apnea, Obstructive, Hypertension, Pulmonary
Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.
The objective of the study is to evaluate the effect of continuous positive airway pressure (PAP) therapy on pulmonary arterial (PA) pressures in acute decompensated heart failure (HF) patients with obstructive sleep apnea (OSA).
- Conditions
- Sleep Apnea, Obstructive, Hypertension, Pulmonary, Heart Failure
- Trial name
- ASAP-HF (NCT02963597)
- Testing
- AirSense™ 10 AutoSet, Standard Medical Therapy
- Where
- 2 sites in United States, Germany
- Volunteers
- 21 people
- Sponsor
- Albert Einstein Healthcare Network
Osteoporosis
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
The aim of this study was to examine the effect of zoledronic acid and alendronate on bone metabolism as measured by biomarkers in postmenopausal women with osteoporosis.
- Trial name
- ROSE (NCT00404820)
- Testing
- Zoledronic acid 5 mg solution, Alendronate 70 mg tablets, Calcium/Vitamin D
- Where
- Germany
- Volunteers
- 604 people
- Sponsor
- Novartis
ASCVD, Elevated Cholesterol
Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability…
- Trial name
- ORION-10 (NCT03399370)
- Testing
- Inclisiran Sodium
- Where
- 145 sites in United States
- Volunteers
- 1,561 people
- Sponsor
- The Medicines Company
Hypertension
Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension
This study will assess the safety and efficacy of aliskiren plus hydrochlorothiazide (HCTZ) in patients who do not achieve controlled blood pressure levels after treatment with another specified antihypertensive medication.
- Trial name
- AMAZING (NCT00867490)
- Testing
- Candesartan+HCTZ - Phase 1, Aliskiren+HCTZ - Phase 2, Aliskiren+HCTZ+amlodipine - Phase 3
- Where
- Germany
- Volunteers
- 186 people
- Sponsor
- Novartis
HIV, Human Immunodeficiency Virus
Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study
The purpose of this study is to determine the safety and bioactivity of an herbal supplement called "kansui," which contains several active ingredients such as ingenols that may have a role in helping clear HIV from the body.
- Trial name
- NCT02531295
- Testing
- Euphorbia kansui extract powder prepared as tea
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, San Francisco
Thyroid Eye Disease
Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study
The overall objective is to evaluate the safety and efficacy of teprotumumab in the treatment of thyroid eye disease (TED) in participants who participated in the lead-in study HZNP-TEP-301 (NCT03298867; OPTIC) and who were…
- Trial name
- OPTIC-X (NCT03461211)
- Testing
- Teprotumumab
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 51 people
- Sponsor
- Amgen
Lymphoma
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
This is a Phase 2, open-label, 2-cohort study designed to evaluate the efficacy and safety of 2 parsaclisib treatment regimens in participants with relapsed or refractory mantle cell lymphoma (MCL) previously treated either with…
- Trial name
- (CITADEL-205) (NCT03235544)
- Testing
- Parsaclisib
- Where
- 103 sites in United States, Belgium and 9 more
- Volunteers
- 162 people
- Sponsor
- Incyte Corporation
Cholera Vaccination
Blood Donor CVD 9000
This is an open-label, non-randomized study. Volunteers will be vaccinated with the oral cholera vaccine, Vaxchora. Vaxchora has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries.
- Trial name
- NCT03724357
- Testing
- Vaxchora
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
HIV-1 Infection
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
During the course of HIV infection the number of CD4 cells decreases, resulting in a reduced immunological response and ultimately immune deficiency.
- Trial name
- IMID (NCT01704781)
- Testing
- Lenalidomide, Vacc-4X, rhuGM-CSF
- Where
- 4 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Bionor Immuno AS
Cancer, Neoplasms
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
This is an open-label, multicenter, 2-part study to determine the recommended Phase 2 dose (RP2D) for GSK2816126 given twice weekly by intravenous (IV) infusion.
- Trial name
- NCT02082977
- Testing
- GSK2816126
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Cognition - Other
Cognition Intervention Study Dortmund
Major aim of this study is to add scientifically proven insights into cognitive effects of meals to the existing recommendations for school meals in Germany.
- Trial name
- CogniDO (NCT01401153)
- Testing
- Skipping lunch
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Research Institute of Child Nutrition, Dortmund
Healthy
Bioequivalence Study Of Diltiazem In 60 Mg Tablets As Tilazem 60® Made by Pfizer, S.A. De C.V., Versus Angiotrofin® 60 Mg Made by Amstrong Laboratorios De Mexico, S.A. De C.V.
This study will research the existance of actual bioequivalence between Diltiazem in 60 Mg Tablets As Tilazem 60® Made by Pfizer, S.A. DE C.V., Versus Angiotrofin® 60 Mg Made by Amstrong Laboratorios De Mexico, S.A. DE C.V.
- Trial name
- NCT01151345
- Testing
- TILACEM, ANGIOTROFIN
- Where
- Mexico
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.